Pedro Goicochea
Biographic Data
| ID | 5874947 |
|---|---|
| NAME | Pedro Goicochea |
| GIVEN NAMES | Pedro |
| FAMILY NAME | Goicochea |
| SIGNATURE | GOICOCHEA P |
| AFFILIATIONS | University of California, San Francisco |
| VERIFIED | No |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 3 |
| AUTHOR COUNT | 6 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2007 |
| LATEST PUBLICATION YEAR | 2015 |
| H-INDEX | 1 |
Defining success with HIV pre-exposure prophylaxis: A Prevention-Effective Adherence Paradigm
Introduction To date, six clinical trials have explored the efficacy of pre-exposure prophylaxis (PrEP) against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged from 0 to 75% [7], the variation of which can largely be explained by differences in PrEP adherence [8]. Efficacy data directly correlate with the objective adherence measures in those studies, and efficacy estimates were between 90 and 100% when ad…
Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study
In the world of HIV pre-exposure prophylaxis (PrEP) research, there is emerging interest in providing study participants with pharmacokinetic results from drug level testing to guide adherence counseling. The iPrEx randomized control trial was the first study to produce meaningful results of PrEP in humans. In the iPrEx open-label extension (OLE) study, blood plasma samples collected in the first 12 weeks of study participation were tested for th…
Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand
In 2008, the Pre-exposure Prophylaxis Initiative (iPrEx) study expanded to include men who have sex with men (MSM) in Chiang Mai, Thailand. In full, 114 participants from Chiang Mai joined this international double-blinded trial of daily FTC-TDF (Truvada®) or placebo as a pre-exposure prophylaxis (PrEP) HIV prevention strategy. To better understand the characteristics of iPrEx participants specifically from this underserved population in Thailand…
Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
BACKGROUND: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. METHODS: We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counse…
Role Versatility Among Men Who Have Sex With Men in Urban Peru
Role versatility refers to the practice in which individual men who have sex with men (MSM) play both insertive and receptive sexual roles over time. Versatility has been thought to be relatively uncommon among Latin American MSM but possibly rising. Versatility has also been shown to be a potentially large population-level risk factor for HIV infection. In this study we examine the correlates of versatile behavior and identity among 2,655 MSM in…
Role Versatility Among Men Who Have Sex With Men in Urban Peru
Role versatility refers to the practice in which individual men who have sex with men (MSM) play both insertive and receptive sexual roles over time. Versatility has been thought to be relatively uncommon among Latin American MSM but possibly rising. Versatility has also been shown to be a potentially large population-level risk factor for HIV infection. In this study we examine the correlates of versatile behavior and identity among 2,655 MSM in…
Role Versatility Among Men Who Have Sex With Men in Urban Peru
Role versatility refers to the practice in which individual men who have sex with men (MSM) play both insertive and receptive sexual roles over time. Versatility has been thought to be relatively uncommon among Latin American MSM but possibly rising. Versatility has also been shown to be a potentially large population-level risk factor for HIV infection. In this study we examine the correlates of versatile behavior and identity among 2,655 MSM in…
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
BACKGROUND: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. METHODS: We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counse…
Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment
Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand
In 2008, the Pre-exposure Prophylaxis Initiative (iPrEx) study expanded to include men who have sex with men (MSM) in Chiang Mai, Thailand. In full, 114 participants from Chiang Mai joined this international double-blinded trial of daily FTC-TDF (Truvada®) or placebo as a pre-exposure prophylaxis (PrEP) HIV prevention strategy. To better understand the characteristics of iPrEx participants specifically from this underserved population in Thailand…
Defining success with HIV pre-exposure prophylaxis: A Prevention-Effective Adherence Paradigm
Introduction To date, six clinical trials have explored the efficacy of pre-exposure prophylaxis (PrEP) against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged from 0 to 75% [7], the variation of which can largely be explained by differences in PrEP adherence [8]. Efficacy data directly correlate with the objective adherence measures in those studies, and efficacy estimates were between 90 and 100% when ad…
Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study
In the world of HIV pre-exposure prophylaxis (PrEP) research, there is emerging interest in providing study participants with pharmacokinetic results from drug level testing to guide adherence counseling. The iPrEx randomized control trial was the first study to produce meaningful results of PrEP in humans. In the iPrEx open-label extension (OLE) study, blood plasma samples collected in the first 12 weeks of study participation were tested for th…
HIV/AIDS Research and Interventions (6 works) · Medicine (6 works) · Men who have sex with men (6 works) · HIV, Drug Use, Sexual Risk (4 works) · Pre-exposure prophylaxis (4 works) · Family medicine (3 works) · Immunology (3 works) · Psychology (3 works) · Adolescent Sexual and Reproductive Health (2 works) · Antiretroviral therapy (2 works)